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ABSTRACT 
 The p300 transcriptional coactivator has been implicated in the development of a 
large number of malignancies; however, the precise mechanism of p300-associated 
tumorigenesis remains unclear.  Here, we demonstrate the functional impact of p300 in 
human melanomas using both genetic and chemical approach.  Depletion of p300 in 
human melanoma cells was associated with cellular growth arrest and senescence. 
Microarray analysis identified the Microphthalmia-associated transcription factor 
(MITF), a critical lineage-specific transcription factor in melanocytes and melanomas, as 
a major downstream target of p300 in human melanoma. Ectopic expression of MITF in 
p300-depleted melanoma cells allowed rescue of the p300-silencing phenotype, 
suggesting a critical regulatory axis involving p300 and MITF. Chromatin 
immunoprecipitation studies revealed direct regulation of MITF transcription through 
p300 acetylation of proximal regulatory domains. Critically, we identified that Forkhead 
		 ix 
Box M1 (FOXM1), a potent pro-proliferation transcription factor, is a target of the p300-
MITF signaling axis. Further evaluation of p300 regulation of melanoma cell growth was 
performed using a highly selective p300/CBP HAT inhibitor, 228-1. Inhibition of 
p300/CBP histone acetyltransferase (HAT) activity was found to significantly inhibit 
proliferation of multiple melanoma lines in an MITF-dependent fashion. Together, these 
data support the role of p300 as a promising therapeutic target in human melanoma and 
suggest particular therapeutic efficacy of small molecule inhibitors of p300 HAT activity 
in tumors expressing high levels of MITF. 
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Chapter I.  Introduction 
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Clinical significance and epidemiology of melanoma 
 Melanoma is a devastating form of skin cancer with poor prognosis. In 2017 
alone, about 87,000 patients will be diagnosed with melanoma (52,000 in men and 
34,000 in women) and 9,000 patients are expected to die of the disease (American Cancer 
Society). Melanoma accounts for less than 4% of all types of cutaneous tumors, but it 
consists of the vast majority of skin cancer deaths (Miller and Mihm, 2006). Melanocytic 
neoplasms can be classified as either benign (melanocytic naevi) or malignant 
(melanomas). Both types of neoplasms originate from melanocytes, which are derived 
from neural crest cells that migrate to skin, eye, and a wide range of other tissues in the 
body during early development (Mort et al., 2015). Melanocytes located at these diverse 
locations in the body can give rise to phenotypically distinct types of melanoma (Bastian, 
2014).  
Melanoma etiology is associated with both environmental and hereditary causes. 
The most prevalent forms of melanoma in Caucasians are identified in regions of skin, 
which sustained chronic exposure to sun (ultraviolet rays). They are often localized in the 
head, the neck and the dorsal surfaces of the extremities of individuals 55 years and older 
(Shain and Bastian, 2016). Fully developed melanomas contain multiple mutations. Most 
common mutations in melanomas are found in key genes that regulate signaling 
pathways, which affect proliferation (BRAF, NRAS, and NF1), metabolism (PTEN, 
KIT), cell cycle regulation (cyclin dependent kinase inhibitor 2A (CDKN2A)), and 
lifespan of cells (TERT) and chromatin remodeling (ARID1A) (Hodis et al., 2012; Huang 
et al., 2013; Krauthammer et al., 2012; Remke et al., 2013) (Table 1).  
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Table 1.  Common mutations identified in melanoma 
 
Molecular pathogenesis of melanoma 
BRAF and NRAS mutations are the most common forms consisting of 53 to 66% 
and 9 to 29% of all melanoma respectively (Goel et al., 2006). Both mutations 
constitutively activate the Mitogen Activated Protein Kinase (MAPK; 
Ras/Raf/MEK/ERK) signaling cascade (Figure I-1). In particular, the importance of 
BRAF mutation was demonstrated in 2002 when 80% of cases harbor a single amino acid 
substitution of valine to glutamic acid while the remainder consists of a valine to lysine 
substitution (Davies et al., 2002). This mutation results in constitutive activation of 
kinase leading to MAPK signaling which is a potent proliferation signal. The presence of 
BRAF mutation was significantly more associated with an earlier age of onset, more 
aggressive clinical course, and lack of chronic sun exposure (Long et al., 2011).  
Pathway Gene Mutation 
MAPK BRAF V600E 
 BRAF V600K, K601E, and G469A 
 NRAS Q61R and Q61K 
 NF1 Deletions, disabling mutations 
Telomerase TERT Promoter mutations 
RB CDKN2A Deletions, disabling mutations 
PI3K PTEN Deletions, disabling mutations 
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Figure I-1. Schematic illustration depicting the MAPK pathway and inhibitors. Adapted from (Eggermont and 
Robert, 2012) 
 
 Identification of driver mutations sheds light on new therapeutic approaches. A 
major development came about when Vemurafenib and Dabrafenib, potent BRAF 
inhibitors, were introduced (Figure I-1). In a randomized phase III clinical trial of 675 
patients, the overall response rate for Vemurafenib was 48% compared to 5% for 
Dacarbazine, an alkylating reagent commonly indicated in melanoma treatment (Korn et 
al., 2008). Furthermore, in a clinical study with 197 patients at a single institution 
reported that patients without BRAF inhibitor treatment showed shorter overall survival 
(Long et al., 2011). Despite the promising clinical trial results, most patients developed 
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resistance and continued disease progression while on treatment. Further investigation 
regarding resistant mechanisms was conducted in a large, phase II Vemuarfenib trial, in 
which tumor samples were collected and analyzed through use of Sanger DNA 
sequencing and sequenom mutation analysis of MAPK/Erk Kinase 1 (MEK1) and 
MAPK pathway (Sosman et al., 2012). Almost all tumors were found to have reactivated 
MAP kinase pathway with elevated phosphorylated-ERK at the time of resistance. 
Additionally, mutations in NRAS and MEK, which are a part of MAPK pathway, in the 
presence of BRAFV600E mutation further suggest the existence of compensating 
mechanisms to maintain MAPK signaling. In order to mitigate the treatment resistance, 
combination therapy of BRAF-inhibitors and MAPK/Erk Kinase (MEK) inhibitor 
(Trametinib; Figure I-1) was tested in a phase 3 clinical study, which resulted in some 
success (Long et al., 2014; Robert et al., 2015). Additional resistance mechanisms have 
been proposed. For example, compensatory activation of MAPK signaling pathway can 
be achieved by acquiring additional loss of function mutations such as Neurofibromatosis 
type-1 (Nf1), which functions as a RAS-GTPase that regulates MAPK signaling 
(Maertens et al., 2013). Additionally, the Cyclic-AMP (cAMP)-dependent melanocytic 
signaling network, which includes G-protein-coupled receptors, adenyl cyclase, protein 
kinase A, and cAMP Response Element Binding protein (CREB) and activates MAPK 
pathway has also been proposed as a mechanism of drug resistance (Johannessen et al., 
2013). Despite pathway-focused research efforts, alternative treatment options for 
patients with drug-resistant melanomas are critically limited. 
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Epigenetic regulation 
The central dogma of molecular biology describes a linear relationship, by which 
the information in genes is converted into proteins. Based on this model, the DNA 
sequence dictates the phenotypic outcome. However, organisms with identical DNA 
sequences often display variety of phenotypes. For instance, identical twins show 
variation in appearance and intellect. Mice that inherited the same DNA can display 
varying coat color and disease inheritance. These are examples that signify the existence 
of mechanisms, which adds complexity to the regulation of gene expression without 
altering DNA sequence. This process is collectively defined as epigenetic regulation. The 
term ‘epigenetics’ was first introduced by Waddington in The Epigenotype, in which he 
describes mechanisms, by which “genes of the genotype bring about phenotypic effects.”  
Epigenetic regulation is made possible by an inherent packaging system, which 
organizes DNA sequences in an organized fashion. The human genome is tightly 
packaged into a fundamental subunit called nucleosome. Each nucleosome consists of a 
histone octamer, which are duplicate copies of histones H2A, H2B, H3 and H4. 146 base 
pairs of DNA wraps around the histone octamer and constitute a larger unit called 
chromatin. It is this structure that allows efficient packaging of DNA sequences. The 
nucleosomes are not static structures. The dynamic modification of histones determines 
way, in which the information is stored and retrieved based on its physical conformation. 
The conformation of the chromatin has a profound impact on gene expression, DNA 
repair and replication. For instance, acetylation of histones allows open and accessible 
conformation of the chromatin, which in turn actives gene transcription and replication 
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while methylation promotes the closed conformation and effectively silences gene 
expression. Collectively, these modifications fall under the category of “epigenetic 
writers.” Erasers, as the name suggests, are responsible for reversal of aforementioned 
epigenetic marks, and epigenetic readers recognize these modifications and recruit 
additional proteins. This dynamic process of epigenetic modifications leads to chromatin 
remodeling and ultimately affects gene expression. Therefore, organisms can rapidly 
respond and adapt to environmental stimuli without altering their DNA sequence. 
Intriguingly, this swift response mechanism can be utilized by human malignancies in 
response to pharmacologic agents that hinder their survival. Epigenetic regulation of gene 
expression may be responsible for rapid development of treatment resistance 
mechanisms.   
 
p300 histone acetyl transferase and epigenetic therapy in melanoma 
Potential therapeutic options for drug-resistant melanomas may be found in 
pharmacologic agents, which alter epigenetic regulation of gene expression. Recent 
discoveries have identified the importance of epigenetic regulation in melanoma biology. 
Novel therapies targeting epigenetic pathways such as DNA methyltransferases and 
histone deacetylases have demonstrated potential for clinical use (Kelly et al., 2010). In 
addition, a variant form of histone (H2A.Z.2) was found to mediate proliferation and drug 
sensitivity of malignant melanoma (Vardabasso et al., 2015). Intriguingly, ARID2 (AT-
rich interactive domain 2), a SWI/SNF chromatin-remodeling complex that is implicated 
in ligand-dependent transcriptional activation, is noted for its potential role on epigenetic 
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regulation in melanoma (Hodis et al., 2012). More importantly, a recently published 
study has identified non-genomic mechanism of acquired drug resistance by 
transcriptomic-methylomic analysis of patient samples before therapy and during disease 
progression, further emphasizing the importance of epigenetic regulation in melanoma 
(Hugo et al., 2015).  
In light of these evidence regarding importance of epigenetic mechanisms in 
development of melanoma, our group has been studying the role of KAT3 family protein 
p300 in melanoma. This protein demonstrates complex roles in cell fate determination in 
both normal and cancerous tissues (Dancy and Cole, 2015; Farria et al., 2015). 
Functionally, p300 acts as a transcriptional co-activator and a scaffold protein. It has 
more than 400 binding partners and is involved in cell cycle regulation, DNA synthesis, 
cellular differentiation, and organ development (Bedford et al., 2010). Importantly, p300 
has histone acetyltransferase (HAT) function, which mediates acetylation on the core 
domains of histones (‘writers’ of epigenetic regulation) (Dancy and Cole, 2015). 
Furthermore, HATs can also exert influence on signaling pathways by catalyzing lysine 
acetylation of many proteins including themselves. There are four major acetyltransferase 
families according to sequence conservation – GANT family (Gcn5 and Pcaf), 
p300/CBP, Rtt109 (not in homo sapiens), and the MYST family (Dancy and Cole, 2015). 
The existence of multiple classes of HATs may suggest a complex mechanism involved 
in epigenetic regulation. More importantly, p300 plays a major role in carcinogenesis. 
p300 has been implicated as a coactivator of known oncogenes, such as c-jun and c-fos. 
A genome-wide SAM (significant analysis of microarray) demonstrated that the p300 
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gene is up-regulated in human melanoma cell lines (Lin et al., 2008). Also, our group has 
previously reported that p300 HAT activity mediates critical growth regulatory pathways 
in tumor cells by promoting cellular responses to DNA damaging agents that are 
currently ineffective against specific cancers (Yan et al., 2013).  
 
Microphthalmia-associated transcription factor 
Microphthalmia-associated transcription factor (MITF) has been established as 
the ‘master regulator’ of melanocyte development, differentiation and pigmentation. 
Germline knockout of MITF in murine models displays complete absence of the 
melanocyte lineage (Goding, 2000). MITF contains basic helix-loop-helix leucine zipper 
(bHLH-Zip) DNA binding motif and regulates gene expression by homo- and hetero-
dimerization and by binding to E-box sequence (CA[C/T]GTG). Nine isoforms of MITF 
exist by utilizing alternate promoters, These isoforms differ in N-termini and show a 
tissue-specific pattern of expression. Melanocytes and melanomas almost exclusively 
utilize M-isoform of MITF (Hershey and Fisher, 2005).  
It has been reported that approximately 5-20% of melanoma has MITF 
amplification, and it is associated with a decrease of five years in survival (Cancer 
Genome Atlas, 2015; Garraway et al., 2005). Silencing of MITF expression is lethal to 
most melanoma cell lines in vitro. In the same study, it was reported that immortalized 
primary melanocytes were able to grow in soft agar when BRAFV600E was co-expressed 
with MITF, suggesting MITF is required for anchorage-independent growth (Garraway et 
al., 2005). Another strong evidence for MITF’s oncogenic role can be found from a 
study, in which a familiarly-associated germline MITFE318K mutation was found to 
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increase the risk of both melanoma and renal cell carcinoma (Bertolotto et al., 2011; 
Yokoyama et al., 2011). Together, it is plausible that MITF functions as an oncogene in a 
subset of melanomas. It is unclear whether dysregulation of MITF pathways exists within 
melanomas without notable mutations in MITF.   
Interestingly, MITF seems to promote distinct disease phenotype based on the 
endogenous level of MITF in melanoma. For instance, MITF-low melanomas are thought 
to be less proliferative and more invasive and MITF-high melanomas are more 
proliferative and less invasive. This observation produced a rheostat model where 
melanoma switches between those two states in response to a variety of environmental 
conditions. It is reported that MITF-low, NF-kB-high, and AXL-high melanoma cell lines 
and tumors are resistant to BRAF inhibitors (Konieczkowski et al., 2014; Muller et al., 
2014). However, the idea that an entire population of melanoma undergoing a total-
phenotype transformation between MITF-high and low status seems to be highly unlikely 
based on an analysis of single-cell quantitative RT-PCR, which suggested that 501 
human melanoma cell lines display heterogeneous levels of MITF expression (Ennen et 
al., 2015). Furthermore, single-cell RNA-sequencing of metastatic melanoma clinical 
samples identified subset of melanoma cells expressing high level of both MITF and 
AXL within tumor microenvironment (Tirosh et al., 2016).  
MITF could serve as an interesting therapeutic target for melanoma therapy due to 
its restricted and specific expression in melanocytic lineages and the critical role it plays 
in melanoma biology. Although MITF-low melanomas do exist and are implicated in 
more invasive phenotype, whether MITF-low status precludes melanomas from utilizing 
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MITF associated pathways in cell maintenance, survival and proliferation remains largely 
unknown. Unlike nuclear hormone receptors or kinases, which can be targeted by 
introducing small molecule inhibitors, targeting of MITF can be challenging. Therefore, 
most of the effort is focused on targeting upstream regulators of the MITF pathway. For 
instance, it was demonstrated that HDAC inhibitors potently downregulate MITF via 
SOX10 repression (Garraway et al., 2005). Another recent study demonstrated that a 
human immunodeficiency virus drug, Nelfinavir, represses PAX3 and subsequently 
silences MITF expression (Smith et al., 2016). A novel compound ML329 was also 
shown to suppress MITF expression (Faloon et al., 2010). A more unique approach to 
silencing MITF was demonstrated by knocking down USP13, which deubiquitinates 
MITF in melanoma cells (Zhao et al., 2011).  
 
Rationale and specific aims 
 Unexpectedly, our preliminary data suggested that silencing p300 correlates with 
reduced MITF expression levels in melanoma cell lines (Figure II-5). Based on the 
importance of MITF in melanoma biology, we hypothesized that silencing of p300 
prohibits cell proliferation via transcriptional regulation of MITF expression in 
melanoma cells. Although it is known that MITF utilizes p300/CBP as a co-factor, it is 
largely unidentified whether p300 directly controls transactivation of the MITF gene 
locus. Targeting p300 may present an opportunity to develop a novel therapeutic strategy 
focusing on suppressing MITF expression level in a subpopulation of melanoma patients.  
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In this dissertation, I will describe my studies using in vitro cell culture systems to 
investigate and understand functional impact of p300 in melanoma. My specific aims are: 
 
1) To evaluate the functional significance of p300 in melanoma development 
and progression and explore molecular pathways associated with p300 
activity. 
 
2) To identify mechanisms involved in transcriptional regulation of MITF by 
p300 in melanoma. 
 
3) To develop novel molecular agents targeting p300 histone 
acetyltransferase activity and assess their potential utility as therapeutic 
agents for melanoma. 
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Chapter II. Results 
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p300 depletion reduces melanoma proliferation by inducing G1-S transition block 
and senescence 
We first aimed to investigate the frequency of the p300 gene alteration present in 
human cancers by utilizing publicly available data sets from The Cancer Genome Atlas 
(TCGA). We analyzed fifty-four human cancers that are available from TCGA and found 
that melanoma patients display about 10% alteration frequency in the p300 gene (n=471), 
half of which are classified as amplification (Figure II-1) (Cerami et al., 2012; Gao et al., 
2013). In line with our analysis, p300 was reported as a part of significant regions of 
chromosomal copy gain in melanoma identified via a comprehensive genomic analysis of 
101 melanoma cell lines (Lin et al., 2008). Together, these findings indicate that p300 
may serve an important role in melanoma disease process.  
In order to investigate the functional role of p300 in human melanoma, our group 
attempted to utilize Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 
to delete p300 (Appendix 1). CRISPR works as an adaptive immune system in bacteria, 
which has been devised to engineer mammalian genome in prompt and efficient manner 
(Barrangou et al., 2007). Unfortunately, the efficacy of CRISPR-mediated p300 deletion 
was not proficient, and the expression level of p300 returned following 5 passages. 
Therefore, it was deemed ineffective to be utilized in our study (Appendix 1). Instead, we 
utilized targeted shRNA to knock down p300 expression in five human metastatic 
melanoma cell lines (WM893B, 451Lu, SK-Mel5, 1205Lu). We confirmed the depletion 
of p300 by western blot and quantitative RT-PCR (Figure II-2A). 48 hours following the 
depletion of p300, melanoma cells displayed morphological changes as compared to the 
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control (Figure II-2B).  In order to evaluate p300’s functional impact on cell 
proliferation, we plated melanoma cells transduced with the indicated shRNA lentiviruses 
into 96-well plates 48 hours post-transduction and subjected the cells to PicoGreen cell 
viability assay (Figure II-2A). Since p300 plays a crucial role as a co-factor for E2F 
transcription factor, which is involved in cell cycle regulation and synthesis of DNA, we 
decided to conduct a cell cycle analysis on p300-depleted cells via flow cytometry. p300-
depleted 451Lu and 1205Lu displayed a significant increase in G1/G0 phase cells and a 
reduction in S and G2/M phase cell population (Figure II-3A) when compared to that of 
control. In addition, p300-depleted melanomas displayed increased ß-galactosidase 
staining (Figure II-3B). Since p300 additionally serves as a mediator of the DNA damage 
response, we hypothesized that the level of γ-H2AX will be elevated following the 
depletion of p300. We found that the level of γ-H2AX is noticeably increased in p300-
depleted melanomas (Figure II-3C).  Together, we conclude that p300 serves a critical 
role in cell proliferation by properly regulating cell cycle and DNA damage response. 
Furthermore, in the absence of p300, melanomas immediately enter senescence.  
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Figure II-1. p300 gene alteration frequency among different types of human tumor   
Melanoma shows approximately 10% p300 alteration (n=471), half of which displays p300 gene amplification. Other 
notable amplification was detected in pancreatic cancer and cholangiocarcinoma. 
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Figure II-2. p300 depletion inhibits melanoma cell proliferation 
(A) Four human melanoma cell lines were transduced with lentiviruses containing pLKO lentiviral vector targeting 
scramble (control) or p300 (sh1 and sh2 are different sequences targeting p300, see materials and methods) for 15 
hours and subjected to puromycin selection for 2 days. Following the selection period, transduced cells were subjected 
to PicoGreen cell proliferation assay. Inset demonstrate western blot confirming efficient silencing of p300 in each 
melanoma cell line.  (B) Melanoma cells display changes in overall morphology following p300 depletion. 
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Figure II-3. p300 depletion induces G1-S transition block and senescence. 
(A) Propidium iodide cell cycle analysis of control and p300-silenced melanoma cell line demonstrates that the 
percentage of G1/G0 phase cells are increased while G2/M phase cells are decreased. (B) ß-galactosidase staining was 
increased after p300 silencing when compared to that of control. (C) Control and p300-depleted cells from three 
melanoma cell lines were assayed for activation of the DNA damage response using antibody against phosphorylated 
H2AX. Error bars, SD; *p<0.05 **p<0.01. 
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Analysis of p300 downstream effector genes in human melanoma cells 
In order to obtain a comprehensive assessment of p300 downstream effector genes in 
human melanoma, we performed a genome-wide expression profiling analysis of 
WM983B and SK-Mel5 melanoma cells following p300 depletion. We identified 666 and 
348 down-regulated genes whose expression levels changed more than 2-fold upon 
silencing p300 in SK-Mel5 and WM983B, respectively. Analysis of the list of down-
regulated genes allowed for the identification of 250 genes downregulated in both cell 
lines defined as p300 downstream target genes in melanoma (Figure II-4A). Ingenuity 
Pathway Analysis (IPA) found these gene sets to be statistically (z-score) enriched for 
downregulation of cell cycle control genes and upregulation of the DNA damage 
response (Figure II-4C). The two highest ranked genes identified in gene set enrichment 
analysis (GSEA) were associated with cell cycle control and DNA replication and 
showed similar negative enrichment scores (Figure II-4B). We further confirmed our 
results via qRT-PCR analysis and found that expression of the p21 cyclin-dependent 
kinase inhibitor CDKN1A was markedly increased following p300 knockdown, while 
expression of Cyclin A2 (CCNA2) was significantly reduced (Figure II-4D), consistent 
with the cellular growth arrest phenotype seen.	
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Figure II-4. Affymetrix gene expression profiling of p300-depleted WM983B and SK-Mel5 cells  
(A) WM983B and SK-Mel5 cells were transduced with lentiviruses containing pLKO lentiviral vector targeting 
scramble (control) or p300 and harvested 48 hours post-transduction for microarray analysis. Two hundred and fifty 
overlapping genes that are downregulated whose expression levels changed >2-fold in both p300-depleted melanoma 
cell lines were subjected to further analysis. (B) Gene set enrichment analysis (GSEA) confirmed that two highest 
ranked signaling pathways are associated with DNA replication and cell cycle. (C) Ingenuity Pathway Analysis (IPA) 
revealed that genes associated with cell proliferation is downregulated and DNA damage checkpoint signaling pathway 
are activated in p300 depleted melanoma cells. (D) qRT-PCR analysis of p21 and CCNA2 level in WM983B and SK 
Mel5 cells following p300 silencing. 
 
p300 depletion correlates with reduced MITF transcription  
We utilized Upstream Regulator analysis (URA) by IPA to identify some of the 
key upstream regulators that are associated with p300. URA determines likely upstream 
regulators that have connection to genes from datasets. URA predicted that MITF was 
affected following p300-depletion (Figure II-5A). Among 250 overlapping down-
regulated genes identified, 33 genes were listed as MITF target genes (Figure II-5B). We 
further confirmed our array results by selecting a few genes from the 33 MITF target 
genes with qRT-PCR. These results were not surprising since p300 serves as a 
transcriptional co-factor for MITF (Sato et al., 1997); however, depletion of p300 also 
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reduced the transcription level of MITF when we further validated the expression profile 
data by qRT-PCR and western blot (Figure II-5C and D). The idea that p300 directly 
regulates the transactivation of MITF locus has not been previously described. 
Interestingly, protein levels of SOX10 and PAX3, which are important transcription 
factor for MITF, were reduced while their transcription level was largely unchanged 
following p300 depletion (Figure II-5E). From these results, we conclude that p300 
depletion in melanoma is correlated with reduced MITF transcription and protein 
expression and suggests that p300 may transcriptionally regulate MITF expression.  
 
MITF controls human melanoma cell proliferation 
Thus far, we have identified that p300-depletion reduced the transcription and 
protein expression of MITF. In order to further confirm the functional impact of MITF in 
our melanoma cell lines, we decided to silence MITF using the shRNA method in four 
melanoma lines (WM983B, 451Lu, 1205Lu, and A375) (Figure II-6A). Morphologically, 
all melanoma cell lines we tested displayed an enlarged and flattened cell phenotype 
following MITF depletion (Figure II-6B). We found that the depletion of MITF 
prohibited cell growth similar to that of p300-depleted melanomas (Figure II-6C). These 
observations demonstrate that MITF is indispensable for melanoma cell proliferation. 
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Figure II-5. p300 transcriptionally regulates MITF 
(A) Two hundred and fifty overlapping genes whose expression levels changed >2-fold in both p300-depleted 
WM983B and SK-Mel5 cell lines were subjected to IPA’s Upstream Regulator Analysis (URA). Shown are the genes 
that were predicted to be activated based on URA (z-score). (B and C) Thirty three common MITF target genes were a 
part of 250 downregulated, overlapping genes in WM983B and SK-Mel5 following p300 depletion. mRNA levels of 
MITF and its target genes were further verified via qRT-PCR. (D) Western blot analysis indicated that MITF protein 
level is reduced along with PAX3 and SOX10, which are important transcription factors for MITF, following p300 
depletion in WM983B. (E) Relative mRNA expression levels of PAX3 and SOX10 and pigmentation associated genes 
(TYRP1 and PMEL) following p300 depletion in WM983B cells are shown. 
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Figure II-6. Depletion of MITF in melanoma reduces cell proliferation  
(A) WM983B cells were transduced with shMITF lentivirus and subjected to western blot analysis. shMITF sequence 4 
and 5 were chosen for further studies. (B) Morphological changes present in melanoma cell lines after MITF depletion 
are shown. (C) Transduced melanoma cell lines with indicated shRNAs were subjected to a cell proliferation assay. (D) 
Side by side comparison of melanoma cell lines transduced with scramble (control; first columns), shMITF (last two 
wells of the upper row) and shp300 (last two wells of the lower row) in four melanoma cell lines. Cells were plated in 
low density (10,000 cells/well) in 6-well dishes and incubated in growth media for two weeks.   
 
 
In order to further confirm whether the expression of MITF is necessary for the survival 
of melanomas in the context of p300 depletion, we decided to ectopically express MITF 
in p300-silenced melanomas. We were able to reconstitute MITF expression in p300-
silenced WM983B and 1205Lu cells (Figure II-7A and B). We utilized the IncuCyte live 
cell analysis system to track groups of cells in real-time over the period of 96 hours. 
Strikingly, p300-silenced WM983B and 1205Lu cells with reconstituted MITF 
expression displayed a significant survival advantage when compared to that of control 
(pCW45-GFP in p300 silenced WM983B) (Figure II-7B and C). Therefore, maintenance 
of MITF expression is crucial for the survival of melanomas in the setting of p300 
depletion. 
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Figure II-7. Ectopic expression of MITF in the setting of p300-depletion confers a survival advantage  
(A) WM983B cells were transduced either with shMITF or shp300 lentivirus and co-transfected with pCW45-GFP or 
pCW45-MITF.  Western blot analysis using antibodies against p300 and MITF is shown. (B) Relative confluence of 
p300-depleted WM983B and 1205Lu cells that are co-transfected with pCW45-GFP or pCW45-MITF was live-traced 
for 96 hours using IncuCyte live cell analysis system. (C) Images of cells following twenty-four, forty-eight, and 
ninety-six hours following the indicated treatment are shown. Error bars, SD; ***p<0.001, ****p<0.0001. 
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p300 controls MITF expression through direct chromatin modifications at upstream 
promoter sites  
Subsequently, we investigated molecular mechanisms of MITF transcriptional 
repression in p300-depleted melanomas. In order to elucidate the mechanism by which 
p300 regulates the transcription of MITF, we decided to use chromatin 
immunoprecipitation (ChIP) assay. We designed 200 base-pair (bp) PCR amplicons, 
which span 2000 bp in the promoter region near the transcription start site (TSS) of MITF 
(Figure II-8). ChIP assay revealed that p300 is abundantly enriched in the promoter 
region near the TSS of MITF gene in WM983B cells (Figure II-9A). We decided to use 
antibodies against acetylated H3K18 and H3K27, which are acetylated by p300, in our 
experiment since they are used as a marker for transcriptionally ‘active’ regions of 
chromosome (Jin et al., 2011). We found that acetylated H3K18 and H3K27 were 
detected in the promoter region of MITF, and p300-depletion dramatically decreased the 
level of acetylated H3K18 and H3K27 in the MITF promoter relative to that of scramble 
controls (Figure II-9B). Consequently, recruitment of RNA polymerase II (RNPII) 
proximal to TSS was notably reduced upon silencing of p300. To further test whether the 
MITF transcription is regulated by p300, reporter assays were carried out using 387bp of 
the proximal human MITF promoter (Figure II-9C). MITF promoter reporter assay 
(Huber et al., 2003) demonstrated that the MITF promoter activity was significantly 
reduced following p300-depletion in human melanoma cells. Together, our data indicates 
that p300 mediates the core histone acetylation in the promoter region of MITF gene 
locus, allowing transcription of MITF to initiate.  
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Figure II-8. Survey of the MITF promoter region 
(A) Approximately 2000bp near the promoter region of MITF gene locus and the location of 200bp PCR amplicons for 
the ChIP assay is illustrated. Of note, PCR amplicons 12 and 13 contain regions that are bound by established 
transcription factors for MITF gene transactivation (SOX10, PAX3, LEF1, CREB (CRE)).  
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Figure II-9. Transcriptional initiation of MITF is inactivated by suppression of acetylation of core histones  
(A) p300 protein is highly enriched in the MITF promoter region. (B) Acetylation of histone H3K27 and H3K18 and 
the recruitment of RNAPII in MITF locus were assessed 48 hours after cells were transduced with indicated shRNAs. 
(C) MITF promoter luciferase assay was conducted in WM983B cells transduced with either scramble or shp300 virus. 
Error bars, SD; *p<0.05. 
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p300-MITF signaling axis transcriptionally regulates FOXM1  
Next, we aimed to further elucidate how p300-MITF signaling contributes to 
proliferative phenotype in melanoma. Upon further analyzing our microarray data, we 
identified that expression of Forkhead Box M1 (FOXM1) was markedly suppressed 
following p300 depletion and target genes of FOXM1 were consistently downregulated 
in both SK Mel-5 and WM983B cells (Figure II-10A).  This is particularly noteworthy 
since pro-proliferative and pro-survival MEK-target FOXM1 has been shown to be an 
important regulator of cell cycle in many human cancers including breast cancer, 
pancreatic cancer, and squamous cell carcinoma (Gemenetzidis et al., 2009; Madureira et 
al., 2006; Wang et al., 2007). Recently, it was reported that many human melanomas also 
express elevated levels of FOXM1 and was demonstrated as a potential therapeutic target 
for metastatic melanoma (Anders et al., 2011; Kruiswijk et al., 2016).  In addition to 
transcriptional repression, FOXM1 protein levels were also reduced following p300 
silencing in three metastatic melanoma cells (Figure II-10B).   
Since we have identified p300-MITF signaling axis as a crucial pathway for 
melanoma survival and proliferation, we hypothesized that MITF controls the expression 
of FOXM1. In order to test this hypothesis, we silenced MITF in three melanoma cell 
lines and investigated the changes in FOXM1 expression. Notably, we observed that 
transcription and protein level of FOXM1 was dramatically reduced following MITF 
depletion in melanoma cells (Figure II-10C and D). This finding is critical since MITF  
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Figure II-10. p300-MITF signaling axis transcriptionally regulates FOXM1 expression  
(A) Fold changes in expression (Log2 value) of FOXM1 and twenty-four FOXM1-regulated genes obtained by 
microarray analysis of p300-depleted SK Mel-5 and WM983B cells is shown. (B) Expression of p300, MITF and 
FOXM1 was assessed with western blot in three melanoma cell lines following p300 depletion. (C) qRT-PCR analysis 
of FOXM1 and cell cycle-associated genes (CDK2, 4, 6 and CCNA2) was performed following MITF-depletion in 
WM983B cells. (D) Western blot analysis using antibodies against MITF, Cyclin A, CDK2 and FOXM1 was 
conducted for three melanoma cell lines following MITF depletion. (E) Reverse phase protein array (RPPA) from 
cutaneous melanoma data set demonstrates that patients with altered p300 and MITF gene status (amplifications in this 
dataset) display a significantly higher level of FOXM1 protein expression. 
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has been regarded as the master regulator of melanoma cell proliferation and survival, yet 
the link between MITF and a potent pro-survival, pro-proliferation FOXM1 has not been 
established. Of note, reverse phase protein array analysis from TCGA cutaneous 
melanoma data set demonstrated that patients with altered p300 and MITF gene status 
(amplifications in this dataset) display a significantly higher level of FOXM1 protein 
expression (Figure II-10E) (Cerami et al., 2012; Gao et al., 2013). These data further 
suggest that p300-MITF signaling axis is critical for proliferative phenotype and survival 
of melanoma by regulating expression of FOXM1.  
In addition to direct transcriptional regulation of FOXM1 by MITF, it is possible 
that phosphorylation of FOXM1, which contributes to protein stability, may have been 
hampered by reduced expression of cyclins and cyclin-dependent kinases following 
MITF depletion. Since CDK2 is directly regulated by MITF (Du et al., 2004), we 
hypothesized that the absence of CDK2 and Cyclin A complex would result in reduced 
phosphorylation of FOXM1 leading to its degradation (Laoukili et al., 2008). Indeed, we 
found that mRNA expression and protein level of CDK2 and CCNA2 was reduced 
following MITF-depletion. We note that MITF-depletion did not affect CDK4 and CDK6 
as much as CDK2 or CCNA2, indicating that phosphorylation of FOXM1 may also be 
regulated by multiple mechanisms (Figure II-10C).  
Following the observation that p300-MITF axis controls the expression of 
FOXM1, we sought to analyze the gene alteration status among 471 melanoma patient 
samples available through TCGA. It has been observed that oncogene mutations that 
activate common pathways often occur in a mutually exclusive manner in human cancers 
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(Thomas et al., 2007). We immediately noticed that the gene alteration pattern for p300, 
MITF, CCNA2, CDK2, and FOXM1 strongly resembles the pattern of mutual 
exclusivity, which suggests that the genes are a part of a common downstream pathway 
(Figure II-11A). Furthermore, we found that 154-altered cases with changes in 
aforementioned genes showed significantly reduced overall survival when compared to 
that of cases without gene alterations (Figure II-11B) (Cerami et al., 2012; Gao et al., 
2013). Together, we conclude that p300-MITF-FOXM1 signaling is critical for 
melanoma proliferation/survival and ultimately affects prognosis in melanoma patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II-11. Alterations in p300-MITF-FOXM1 and cell cycle-associated genes display a pattern of mutual 
exclusion and determine overall survival.  
(A) Gene alterations in p300, MITF, CCNA2, CDK2, and FOXM1 display patterns of mutual exclusion. Tumor 
samples are shown in columns; genes in rows. Only samples with at least one alteration are shown. (F) Overall survival 
was significantly lower in the cohort of 154 patients with gene alterations shown in (A).  
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Characterization of a selective p300/CBP HAT inhibitor 228-1 
Since p300-mediated histone acetylation appears to play a major role in regulating 
MITF transcription (Figure II-9), we sought to evaluate if targeted inhibition of p300-
mediated lysine acetylation is sufficient to block MITF transcription and inhibit 
proliferation in melanoma. In order to test this hypothesis, our group initially developed 
and characterized a selective p300/CBP HAT inhibitor, compound R (Appendix 4), 
which was later substituted by structurally similar HAT inhibitor, 228-1. 228-1 was 
synthesized as described as a racemic mixture in patent (WO 2016044770 A1 20160324) 
(Michaelides et al., 2016) (Appendix 3). To confirm that 228-1 is a potent inhibitor of 
p300 acetyltransferase activity, we performed an in vitro experiment with recombinant 
purified full-length p300 enzyme and purified histone H3 substrate. We used 14C-acetyl-
CoA and monitored 14C incorporation into H3 using phosphorimage analysis. It was 
determined that 228-1 blocks p300 acetyltransferase activity with IC50 at 0.5µM 
(Appendix figure 2). Upon treatment with 228-1, WM983B and 451Lu cells were 
morphologically altered and resembled the shape of human primary melanocytes (Figure 
II-12B). We decided to further investigate a set genes associated with melanocytes and 
melanomas. Interestingly, levels of transcription of PAX3 and SOX10 were increased 
following 228-1 treatment while protein levels for PAX3 and SOX10 were similar and 
slightly reduced, respectively (Figure II-12D). Furthermore, MITF and its target genes 
TYRP1 and PMEL were markedly reduced (Figure II-12C). 228-1 treatment in WM983B 
cells demonstrated that concentrations of 5 and 10µM effectively inhibited the acetylation 
of histone H3 at lysine 18 while sparing lysine 9, a site in a histone that is not 
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preferentially acetylated by p300/CBP (Figure II-12C). More importantly, MITF protein 
expression was dramatically suppressed with 5 and 10µM of 228-1 treatments while the 
protein levels of p300 and CBP remained unchanged. This result strongly supports our 
hypothesis that the proper acetylation of MITF promoter is necessary to transactivate 
MITF locus while the mere presence of p300 or CBP, a close homolog of p300, is not 
sufficient to initiate MITF transcription.   
Since we identified that FOXM1 is regulated by the p300-MITF signaling axis, 
we decided to further confirm whether 228-1 treatment would control FOXM1 
expression in a similar fashion. Consistent with our previous results, 228-1 treatments in 
WM983B and 451Lu cells dramatically reduced the transcription of MITF, CDK2, 
CCNA2, and FOXM1 (Figure II-12E). In addition, protein levels of FOXM1 were 
reduced along with a complete ablation of MITF, CDK2 and Cyclin A protein expression 
following 228-1 treatments in three metastatic melanoma cell lines (Figure II-12F).  
These results suggest that p300 HAT inhibition, by downregulating MITF expression, 
potently blocks the expression of a pro-proliferative FOXM1 in metastatic melanomas. 
Considering the fact that FOXM1 serves as a major regulator of cell proliferation, we 
decided to test if 228-1 treatments would induce senescence. Consistent with our data, 
both WM983B and 451Lu cells showed marked increase in ß-galactosidase staining after 
7 days of 228-1 treatment (10µM) (Figure II-12G). In addition, we utilized additional 
marker of senescence, promyelocytic leukemia (PML) in our analysis. We found that 
WM983B cells displayed increased intensity of PML staining and a significant increase 
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in the number of PML bodies following 7-day treatment with 228-1(10µM) (Figure II-
12H and I).  
 
 
 
Figure II-12. Characterization of a selective inhibitor of p300 HAT, 228-1  
(A) A chemical structure of 228-1 is illustrated. (B) Cell morphology change following 228-1 treatments (5µM) for 72 
hours. (C) mRNA levels of genes associated with MITF is assessed via qRT-PCR. (D) WM983B cells were subjected 
to different concentrations of 228-1 in vitro and analyzed by western blot. 5 and 10 uM concentrations were potent 
enough to block H3K18 acetylation and MITF transcription. (E and F) Relative mRNA and protein levels of MITF, 
CDK2, CCNA2 and FOXM1 in 228-1 treated melanoma cells (MITF-high group) were compared with that of control. 
(G) ß-galactosidase staining was performed on melanoma cells following 228-1 treatments (10µM) for 7 days. (H) 
Antibody against PML was used to evaluate the number of PML bodies in the nucleus following 228-1 treatments 
(10µM) for 7 days.  (I) Quantification of the number of PML bodies is shown. Error bars, SD; ***p<0.001.  
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228-1 induces robust growth inhibition in melanoma cell lines with high levels of 
endogenous MITF 
Our library of melanoma cell lines includes melanoma cell lines that display 
variable baseline expression levels of MITF (Figure II-13A). Based on our findings, we 
hypothesized that 228-1 treatment in melanomas with a high-baseline MITF expression 
would display a robust inhibition of proliferation when compared to that of low-baseline 
MITF expressers. Our results strongly indicate that FOXM1 expression is regulated by 
MITF; therefore, we postulated that reduced transcription of MITF following 228-1 
treatments would be detrimental to melanomas with high levels of MITF. As expected, 
melanomas with high-MITF expression displayed a significantly greater inhibition in 
proliferation compared to that of low-MITF expression groups (Figure II-13B and C). 
Consistent with our 228-1 treatment data, we observed that silencing of p300 in 228-1 
treatment-resistant A375 cells displayed a slight growth inhibition and lack of ß-
galactosidase staining (Figure II-13D and E). Together, these data support the role of 
p300 as a promising therapeutic target in human melanoma and suggest particular 
therapeutic efficacy of small molecule inhibitors of p300 HAT activity in tumors 
expressing high levels of MITF. 
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Figure II-13. Melanoma cells with high endogenous MITF expression displays robust inhibition of proliferation 
following 228-1 treatment  
(A) A panel of melanoma cell lines expressing various levels of MITF was verified by western blot and qRT-PCR. 
Based on the absolute MITF transcript number, we divided cell lines into MITF low and high groups (red dotted line) 
(B) Melanoma cells were subjected to 6-day treatment with 228-1 (10µM). (C) MITF-high expressers responded more 
robustly to 228-1 treatment when compared to that of MITF-low expressers. (D) Silencing of p300 in A375 cells and 
proliferation assay is shown. (E) ß-galactosidase staining of A375 following transduction with control and shp300 
expressing lentiviruses. Error bars, SD; ***p<0.001. 
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Figure II-14. Schematic model illustrating the p300-MITF-FOXM1 transcriptional axis regulating melanoma 
cell growth. 
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Materials and Methods 
Cell culture  
Melanoma cell lines were kindly provided by Dr. Meenhard Herlyn at the Wistar Institute 
(Philadelphia, PA) and Dr. Levi Garraway at the Broad Institute (Cambridge, MA). 
Melanoma cells were maintained in Dulbecco’s modified Eagle medium. The medium 
was supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin (pen-
strep), and 1% L-glutamine. The media, pen-strep, L-glutamine, and FBS were purchased 
from Invitrogen. All cell lines were grown at 37 °C in an atmosphere containing 5% CO2.  
 
Plasmids and transfection 
Lentiviral expression vectors pCW45-GFP and pCW45-MITF were kindly provided by 
Dr. David Fisher (Massachusetts General Hospital, Boston). pGL2-MITF and control 
vector were generous gifts from Dr. Widlund (Brigham and Women’s Hospital, Boston). 
The Lentiviral pLKO1-based shRNA vectors targeting p300 and MITF were purchased 
from Sigma Aldrich (St. Louis, MO). Packaging and envelope expressing plasmids 
(psPAX2 and pMD2.G) were gifts from Didier Trono (Addgene plasmid #12260).  
 
 
Lentivirus production 
Selected p300 and MITF shRNA plasmids were co-transfected into HEK293T cells along 
with expression vectors containing lentiviral envelope and packaging plasmids via 
Lipofectamine 2000 according to the manufacturer’s protocol. Lentiviruses were 
harvested 48 hours following transfection. 250,000 human melanoma cells were 
transduced with each harvested lentivirus (500µL) in the presence of 8 µg/mL of 
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polybrene. Subsequently, melanoma cells transduced with pLKO1-based shRNAs were 
selected in 1.5 µg/mL of puromycin after 48 hour following transduction in their 
respective culture medium. Information regarding p300 shRNAs used in this study is 
described in a previous publication (Dancy et al., 2012). 
 
Cell treatment with a small molecule inhibitor  
To treat cells, compound 228-1 was dissolved in anhydrous DMSO to make a 10 mM 
solution and added to culture medium to the desired concentration. An equal amount of 
DMSO was used as the vehicle control.  
 
Cell cycle analysis  
Cells were stained with propidium iodide according to a published protocol 
(Darzynkiewicz et al., 2001). Data acquisition and analysis were performed on a 
FACSCalibur flow cytometer with the CellQuest software (BD Biosciences, San Jose, 
CA).  
 
Microarray studies  
RNA from melanoma cells transduced with either shp300 or scrambled lentiviruses was 
purified using the Qiagen RNAeasy Plus Kit. Samples were submitted to Boston 
University Microarray and Sequencing Resource Core Facility for analysis on the 
Affymetrix GeneChip Human Gene 2.0 ST. The initial data processing and 
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normalizations were performed by the core facility. The gene ontology analysis was 
performed with Ingenuity Pathway Analysis (Qiagen, Redwood City, CA).  
 
qRT-PCR  
Complementary DNA was synthesized using the Superscript III First Strand Synthesis 
System (Invitrogen, Grand Island, NY). qRT-PCR was performed using the SYBR Green 
PCR Master Mix (ABI/ Invitrogen) as described previously (Yan et al., 2013). The 
primer pairs were designed using the NCBI PrimerBlast tool and individually optimized. 
Gene expression values were determined with the ∆∆Ct method. GAPDH was used as an 
internal control. The absolute copy number of MITF was determined by using a standard 
curve generated from a 500bp MITF amplicon with varying concentrations. The list of 
primers used in this study is provided in the supporting information. 
 
ChIP assay followed by qPCR  
ChIP was performed based on a previously described protocol (Yan et al., 2013). The 
antibodies used in the study include normal rabbit and mouse IgG (sc-2027x and sc-2025, 
Santa Cruz), or antibodies against p300 (sc-585, Santa Cruz), histone H3K18 (13998, 
Cell Signaling), histone H3K27 (8173, Cell Signaling), or RNA polymerase II (2629, 
Cell Signaling). Primers for qPCR were designed to amplify a region near transcription 
start (Appendix 6). qPCR was performed using SYBR Green PCR Master Mix (ABI/ 
Invitrogen) on StepOnePlus real time PCR system (Applied Biosystems). 
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Histone acetyltransferase assays 
Histone acetyltransferase assays were performed as described previously (Zucconi et al., 
2016). Briefly, reactions measured the p300-catalyzed incorporation of 14C from the 
acetyl-CoA substrate (60mCi/mmol) into purified histone H3. 228-1 was dissolved in 
100% DMSO and diluted in 10% DMSO for a final reaction concentration of 1%. 
Reactions were performed in a buffer composed of 50 mM HEPES (pH 7.9), 50 mM 
NaCl, 1 mM TCEP, and 25 ug/ml BSA at 30˚C and initiated by the addition of 14C-
acetyl-CoA to a final concentration of 200 nM.  After 5 minutes, the reaction was 
quenched and acetylated histone product was separated on a 16% tris-tricine gel and 
visualized by autoradiography. A 14C-BSA standard was run in parallel and used to 
quantify product formation. 
 
Western blotting 
Whole-cell lysates were prepared as described in the supplement. Western blots were 
performed as previously described (Cummings et al., 2008). A complete list of primary 
and secondary antibodies used in this study is included in the supplemental information.  
 
Senescence detection  
Senescent cells were detected by staining for lysosomal senescence-activated beta-
galactosidase activity with a commercial kit from Cell Signaling Technology (#9860) and 
by immunofluorescent staining of promyelocytic leukemia protein nuclear bodies using 
an established protocol (Vernier et al., 2011).  
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Chapter III. Discussion 
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Over the last two decades, epigenetic regulation of DNA-based processes such as 
DNA methylation and histone modification has been intensely studied (Kulis and 
Esteller, 2010; Rodriguez-Paredes and Esteller, 2011; Sarkar et al., 2015). Our group has 
previously characterized an inhibitor of p300/CBP HAT activity, C646, in order to 
evaluate its functional contributions to tumor development and progression (Bowers et 
al., 2010; Yan et al., 2013). We reported that C646 inhibits the growth of human 
melanoma by promoting sensitivity to DNA-damaging agents and enhancing apoptosis in 
melanoma cells. Global assessment of the p300 HAT transcriptome revealed that 
functional roles such as cell cycle progression, chromatin assembly, and DNA repair 
pathways are involved. We report in this present study that silencing of p300 in 
melanomas can be potential therapeutic strategy for melanoma, which is consistent with 
our previous studies. Furthermore, we developed and utilized an improved p300/CBP 
HAT inhibitor 228-1, which demonstrates a 20-fold increase in potency compared to 
C646 (Dancy et al., 2012), as a tool to evaluate target genes specifically associated with 
p300 HAT function. There exist numerous pharmacologic reagents that are designed 
specifically for HDAC and methyltransferases; however, only a handful of compounds 
that target p300/CBP HAT activity with lesser specificity are available for research 
(Sarkar et al., 2015). We believe that 228-1 would serve as an important tool in the field 
of epigenetic research. 
Notably, we discovered that p300 HAT activity regulates the transactivation of 
MITF gene locus quite specifically through epigenetic modification of core histones. We 
provided evidence to suggest the existence of a p300-MITF signaling axis that may 
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determine the fate of melanoma survival in vitro. In the past, other studies have identified 
multiple upstream transcriptional regulators that are implicated in directly transactivating 
(SOX10, PAX3, CREB and Wnt-3a) or suppressing (AXL, BPTF, FOXD3 and BRN-2) 
the transcription of MITF; however, regulation of MITF expression via epigenetic 
mechanisms has not been yet reported (Bertolotto et al., 1998; Dar et al., 2016; Goodall 
et al., 2008; Kubic et al., 2008; Sensi et al., 2011; Shakhova et al., 2012; Takeda et al., 
2000; Widlund et al., 2002). Machineries that control the precise recruitment and 
acetylation of the MITF promoter by p300 still remains to be discovered; nonetheless, our 
findings suggest a different approach that melanomas could take to control the expression 
of MITF. In addition, epigenetic modification by p300 may affect the outcome of three-
dimensional chromosome folding within the MITF locus, which may affect expression 
(Dekker et al., 2002; Harmston and Lenhard, 2013). Recent advancement in molecular 
and genomic approaches can be utilized to study the frequency with which pair of loci in 
the genome are connected and may provide new insights into the uncharted epigenetic 
landscape in melanoma (Nagano et al., 2015; Schmitt et al., 2016). 
Furthermore, we identified that a potent pro-proliferative signal FOXM1 is 
controlled by the p300-MITF signaling axis in melanoma. As a member of the forkhead 
box family of transcription factors, FOXM1 is activated during the G1 phase of the cell 
cycle and plays an important role during the S phase and mitosis by regulating 
transcriptional activity of a number of genes crucial for cell cycle progression (Kim et al., 
2006; Wang et al., 2002; Ye et al., 1999). Importantly, FOXM1 is implicated in 
promoting proliferation in a wide range of human malignancies including breast cancer, 
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gliomas, colorectal cancers, lung adenocarcinomas, hepatocellular and prostate 
carcinomas (Bates and Harper, 2002; Kalin et al., 2006; Kalinichenko et al., 2004; Kim et 
al., 2006; Liu et al., 2006; Wang et al., 2005; Wonsey and Follettie, 2005; Yoshida et al., 
2007). Despite mounting evidence that FOXM1 serves an influential role in human 
cancers, its impact on melanoma has not been extensively studied until recently. (Anders 
et al., 2011; Ito et al., 2016; Kruiswijk et al., 2016). We provide strong evidence in this 
study to suggest that silencing the p300-MITF signaling effectively suppresses FOXM1 
expression in human metastatic melanomas. Of note, a direct or indirect regulatory 
relationship between MITF and FOXM1 has not been characterized in the past. 
Considering FOXM1’s critical role as a pro-survival, pro-proliferative signal, our 
findings provide a rationale for the treatment of melanoma by suppressing FOXM1 via 
epigenetically targeting p300-MITF signaling axis with small molecule inhibitors of p300 
HAT activity (Figure II-14). 
The aggressive nature of melanoma is thought to be attributed by its neural crest 
origin, a highly migratory and multipotent embryonic cell population that gives rise into 
diverse lineages of cells including melanocytes (Simoes-Costa and Bronner, 2015). The 
process of phenotype switching is crucial for initiating the hard-wired lineage programs 
for proper differentiation (Li et al., 2015; Takahashi et al., 2013). This developmental 
characteristic of melanoma highlights the need to elucidate underlying molecular 
mechanisms. Studies on MITF expression patterns in melanoma may hold important 
insights that may explain a potential mechanism governing phenotype switching. There 
exist many candidate genes that are implicated in controlling MITF levels and phenotype 
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switching between proliferative versus invasive stage; however, the precise relationships 
between those genes are yet to be defined (Konieczkowski et al., 2014; Muller et al., 
2014). In addition, varying MITF expression levels could possibly control intra- and 
inter-tumor heterogeneity in melanoma and affect clinical outcomes (Roesch, 2015). 
Further studies on epigenetic regulations that occur on a single-cell level in regards to 
MITF expression could potentially address questions regarding phenotype switching and 
tumor heterogeneity (Carstens et al., 2016; Nagano et al., 2013).  
One of major obstacles in treating melanoma compared to other malignancies is 
de novo and acquired BRAF-inhibitor resistance (Hugo et al., 2015; Johannessen et al., 
2013; Konieczkowski et al., 2014; Muller et al., 2014; Roesch, 2015; Sun et al., 2014). 
Molecular mechanisms underlying treatment resistance have been under close scrutiny. 
Recent studies have identified that expression of AXL, a member of TAM family of 
receptor tyrosine kinases, is negatively correlated with MITF expression and implicated 
in de novo and early stages of acquired BRAF-inhibitor resistance (Konieczkowski et al., 
2014; Muller et al., 2014; Sensi et al., 2011). In contrast to these reports, Smith and 
colleagues elegantly demonstrated that HIV1 protease inhibitor Nelfinavir suppresses 
MITF expression induced by MAPK pathway inhibitor in melanoma cells and sensitizes 
melanoma cells with NRAS or BRAF mutation to MEK inhibitors (Smith et al., 2016). 
Our group also reported in this study that treatment with p300/CBP HAT inhibitor 228-1, 
demonstrates robust melanoma growth inhibition in high MITF expressers. On the basis 
of our current data, we suggest that future studies should emphasize the impact of HAT 
inhibition, either as an individual treatment or in conjunction with BRAF-inhibitor, on 
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melanomas that have developed resistance. In addition, continuous research on increasing 
specificities of epigenetic modifications in an effort to minimize general toxicities and 
off-site target effects is essential.  
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Appendix 1 – EP300 knockout via CRISPR-Cas9 
 
Proliferation and cell cycle analysis of p300-null melanoma cell lines engineered by 
CRISPR/Cas9 system.   
In this aim, we will use a cell culture system based approach to introduce a loss of 
function mutation to characterize the role of p300 in multiple human melanoma cell lines. 
We will focus on the impact of p300 loss of function mutation engineered by 
CRISPR/Cas9 system on proliferation rate and metastatic potential. Furthermore, the 
p300-null human melanoma model system could shed important insights into potential 
combination therapy with other chemotherapy reagents currently used in the clinic.  
The goal of this aim is to generate p300 knocked out melanoma cells line and to 
assess proliferation and cell cycle status. We achieved this by utilizing Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR) technology. CRISPR works 
as an adaptive immune system in bacteria, and it has been devised to engineer 
mammalian genome in prompt and efficient manner (Barrangou et al., 2007). In this 
system, a guide RNA (sgRNA) directs Cas9 nuclease in a sequence-specific manner to 
cause double-stranded cleavage (Jinek et al., 2012). Deep sequencing of targeted locus 
has revealed that repair of Cas9-induced cleavage results in non-homologous end-joining 
(NHEJ), causing small insertion/deletion mutation (INDEL) (<20bp) in the target 
sequence region, with small sequence insertions and substitutions (<30bp) at much lower 
frequency. Furthermore, off-target activity of CRISPR/Cas9 is minimal (Wang et al., 
2014). Taken together, evidence indicate that CRISPR/Cas9 is an efficient means of 
generating loss of function alleles. 
		
49 
To achieve this loss of function mutation, we utilized the doxycycline inducible 
pCW-Cas9-FLAG vector (Wang et al., 2014). Upon initiation of doxycycline treatment, 
transduced melanoma cell lines expressed FLAG tagged humanized Cas9 protein. 
Initially, Cas9-expressing melanoma cell lines were generated using lentiviral 
transduction of the doxycycline-inducible pCW-Cas9 vector. We then selected single-cell 
colonies with greatest fold-change in Cas9 and FLAG expression. Subsequently, selected 
single cell clones were infected with guide sgRNA targeting p300 (sgp300) and non-
targeting sequence as control (sgCTR) and induced for Cas9 expression via doxycycline 
(2µg/ml) treatment for 10 days. Assessment of cleavage efficiency was determined by the 
Surveyor nuclease assay as described before (Wang et al., 2014). Based on the location of 
the sgp300 guide RNA and the primer used for the Surveyor assay, we expected to obtain 
bands of two sizes. We predicted that Cas9 cleavage of EP300 exon 1 with sgRNA1 and 
sgRNA2 would produce 400bp-200bp and 460bp-140bp, sized bands, respectively 
(Appendix Figure 1A). Indeed, our data produced the expected result, although the 
efficiency of the cleavage was less than optimal when compared to previously reported 
case using different guide RNAs (Wang et al., 2014) (Appendix Figure 1B). This result 
indicates that only a minor subset of melanoma cells induced with doxycycline had a 
Cas9-mediated NHEJ event. It is possible that cells have lost robust expression of Cas9 
following a single cell colony selection. It is not uncommon to observe silencing of 
expression vectors utilizing bacterial promoters (such as CMV) in ‘stably’ transduced 
cells due to hypermethylation (Hsu et al., 2010). It is also feasible that the guide RNA 
could not efficiently recruit Cas9 to the targeted region in the genome. Interestingly, p300 
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protein expression level was dramatically reduced despite the low-Cas9 recombination 
efficiency. The suppression of p300 protein was further confirmed by reduced acetylation 
of K18 on histone H3 and MITF. It seems plausible that sgRNAs may function similar to 
shRNAs by hindering protein translation by binding to anti-sense mRNA sequence. Yet 
another possibility of reduced induction is due to contamination of the single cell colony 
procedure. It is possible that the single cell colony is not truly derived from a single clone 
but multiple cells. It would mean that the cells will have a different level of Cas9 
expression and recombination of p300 would not occur as efficiently through the cell 
population.  
Despite a low recombination efficiency, 451Lu cells displayed enlarged nucleus 
and spread-out cell morphology compared to that of control. We further confirmed the 
efficiency of the recombination via western blot. Two melanoma cell lines we used for 
the experiment demonstrated that the level of p300 expression was reduced following the 
Cas9-mediated recombination (Appendix Figure 1C). Furthermore, MITF expression was 
concomitantly reduced as we expected. The reduction in acetylated histone 18, which is 
preferentially acetylated by p300, further indicates that the silencing of p300 was 
effective and demonstrates a physiological impact in in vitro system. It is interesting to 
note that acetylated histone 9, which is not robustly acetylated by p300, was also reduced 
indicating that guide RNA targeting p300 may have some offsite target effect potentially 
on the expression of CBP (Appendix Figure D). It is also interesting to note that Cas9-
mediated recombination in 451Lu cells may have produced a non-functional p300 protein 
that is shorter in length as evidenced by the western blot analysis (Appendix Figure D). 
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This indicates that the same guide RNA sequence utilized for Cas9 endonuclease activity 
may produce protein products of different lengths depending on the type of cell lines we 
use for the experiment.  
Although this experiment proved that the sequestration of p300 expression can be 
achieved the CRISPR technology, the low rate of recombination was deemed inadequate 
and unreliable to be utilized in our study. Furthermore, p300-deleted 451Lu cells from 5 
clones regained the p300 expression level following 5 passages, indicating that some 
cells have escaped the recombination process and out grew and replaced the p300-deleted 
cells. 
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Appendix figure 1. Genetic knockdown of p300 in human melanoma 
(A) Approximate locations of two EP300 sequence-specific guide RNAs (sgRNA1 and 2) targeting the exon 1 of p300 
gene on chromosome 22. Cas9-mediated double strand DNA breakage will occur at the indicated location in the 
Surveyor assay primers and produce INDEL mutation. Surveyor assay is expected to yield amplicons of size 400bp and 
200bp for sgRNA1 and 460bp and 140bp for sgRNA2.  (B) 451Lu cells were co-transduced with a doxycyclin-
inducible lentivirus expression vector pCW-Cas9 and guide RNAs. Single cell colonies of transduced cells were 
collected. Transduced cells were then induced to express Cas9 by treating with docxycyclin (2ug/ml) for 10 days. 
Surveyor assay was conducted to verify p300 knockout, and the result is shown above. (C) 451Lu cells displayed 
change in overall morphology following doxycycline induction.  (D) Western blot analysis using antibodies against 
p300, CBP, MITF and acetylated lysine 9 and 18 of histone H3.  ß-actin was used as a loading control.  
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Appendix 2 – Confirmation of HAT inhibition by 228-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix figure 2. 228-1 inhibits p300 acetylation of histone H3 
Histone acetyltransferase assays with 2 nM p300, 20 uM H3, 200 nM 14C-acetyl-CoA and variable concentrations of 
228-1. Duplicate reactions run in adjacent lanes (upper panel). Graph of the data in the lower panel shows an EC50 
~0.5uM. Error bars represent SEM.  
 
 
 To confirm 228-1's effects as an inhibitor of p300's acetyltransferase activity, we 
performed an in vitro experiment with recombinant purified full-length p300 enzyme and 
purified histone H3 substrate.  We used 14C-acetyl-CoA and monitored 14C incorporation 
into H3 using phosphorimage analysis. It was shown that 228-1 blocks p300 
acetyltransferase activity with IC50 ~0.5 µM.  We estimate that this is at least 20-fold 
more potent than C646 based on comparable assay conditions (Dancy et al., 2012). 
 Histone acetyltransferase assays were performed as described previously. Briefly, 
reactions measured the p300-catalyzed incorporation of 14C from the acetyl-CoA 
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substrate (60mCi/mmol) into purified histone H3.  228-1 was dissolved in 100% DMSO 
and diluted in 10% DMSO for a final reaction concentration of 1%. Reactions were 
performed in a buffer composed of 50 mM HEPES (pH 7.9), 50 mM NaCl, 1 mM TCEP, 
and 25 ug/ml BSA at 30˚C and initiated by the addition of 14C-acetyl-CoA to a final 
concentration of 200 nM.  After 5 minutes, the reaction was quenched and acetylated 
histone product was separated on a 16% tris-tricine gel and visualized by 
autoradiography. A 14C-BSA standard was run in parallel and used to quantify product 
formation. 
 
*Data and figure produced by Beth Zucconi 
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Appendix 3 – Synthesis of 228-1 
 
 
 
 
Appendix figure 3. Synthesis of 228-1 
 
(S)-1,1,1-trifluoro-N-(4-fluorobenzyl)propan-2-amine (1):  Followed procedure reported 
M. Michaelides, et al.  1H NMR (500 MHz, CHLOROFORM-d) ∂ 7.31 (dd, J = 5.50, 
8.49 Hz, 2H), 7.02 (t, J = 8.72 Hz, 2H), 3.78 - 3.98 (m, 2H), 3.17 (spt, J = 6.97 Hz, 1H), 
1.26 (d, J = 6.76 Hz, 3H).  LC-MS: Rt=1.62 min; m/z=222.0 [M+H]+ 
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(S)-2-bromo-N-(4-fluorobenzyl)-N-(1,1,1-trifluoropropan-2-yl)acetamide (2):  Followed 
procedure reported M. Michaelides, et al.  1H NMR (500 MHz, CHLOROFORM-d) ∂ 
6.94 - 7.22 (m, 4H), 5.49 (quind, J = 7.81, 15.12 Hz, 0.64H), 5.05 (d, J = 16.35 Hz, 
0.39H), 4.59 - 4.82 (m, 1.37H), 4.47 - 4.59 (m, 0.35H), 4.22 (d, J = 15.88 Hz, 0.35H), 
4.06 (d, J = 11.00 Hz, 0.37H), 3.92 (d, J = 10.69 Hz, 0.37H), 3.69 (s, 1.31H), 1.23 - 1.47 
(m, 3H).  LC-MS: Rt=2.70 min; m/z=342.0 [M+H]+ 
 
1-methyl-3-(1-oxo-2,3-dihydro-1H-inden-5-yl)urea (3):  To a magnetically stirred 
solution of 5-amino-2,3-dihydro-1H-inden-1-one (1.00 g, 6.79 mmol) in THF (34 ml) 
was added triethylamine (2.8 ml, 20.4 mmol, 3.0 equiv.) followed by the addition of 
triphosgene (0.81 g, 2.71 mmol, 0.4 equiv.) in one portion at rt.  After stirring for 30 min 
at rt, methylamine (2M THF, 13.6 ml, 4.0 equiv.) was added in small portions over 5 
min.  After stirring overnight (~18 h) at rt, volatiles were removed in vacuo and the 
residue was dissolved in EtOAc and water.  The aqueous layer was extracted with EtOAc 
(3 x 15 ml), and the combined organic layers were washed with brine.  After loading the 
organics onto silica gel, the crude product was purified over silica gel using a gradient of 
hexanes/EtOAc (0 to 100%) to provide 726 mg of 3 as an off-white solid (52% yield).  1H 
NMR (500 MHz, METHANOL-d4) ∂ 7.69 - 7.78 (m, 1H), 7.59 (d, J = 8.33 Hz, 1H), 7.29 
(dd, J = 1.81, 8.41 Hz, 1H), 3.05 - 3.15 (m, 2H), 2.79 (s, 3H), 2.60 - 2.71 (m, 2H).  LC-
MS: Rt=1.46 min; m/z=205.2 [M+H]+ 
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1-(1-cyano-1-((trimethylsilyl)oxy)-2,3-dihydro-1H-inden-5-yl)-3-methylurea (4):  
Procedure is a slight modification to that found in the literature. (Kim et al.) A Biotage 
microwave vial was charged with 3 (0.96 g, 4.70 mmol, 1 equiv.), anhydrous MeCN (4.7 
ml), trimethylsilyl cyanide (1.19 ml, 9.41 mmol, 2 equiv.) and 4-methylmorpholine N-
oxide monohydrate (27 mg, 0.24 mmol, 0.05 equiv.).  The vial was sealed and heated via 
a Biotage microwave at 100°C for 1 h.  After heating, the volatiles were removed in 
vacuo, and the crude product was used in the next step without further purification.  
Crude-1H NMR (500 MHz, CHLOROFORM-d) ∂ 7.44 (d, J = 8.17 Hz, 1H), 7.40 (s, 1H), 
7.10 (dd, J = 1.81, 8.25 Hz, 1H), 6.38 (s, 1H), 4.67 (br. s., 1H), 3.03 - 3.13 (m, 1H), 2.90 - 
2.99 (m, 1H), 2.86 (s, 3H), 2.71 (ddd, J = 6.05, 7.66, 13.32 Hz, 1H), 2.43 (ddd, J = 5.42, 
7.74, 13.09 Hz, 1H), 0.19 (s, 9H). LC-MS: Rt=2.51 min; m/z=304.1 [M+H]+ .  Also 
observed in the LC/MS Rt=1.45 min; m/z=232.1 [M+H]+ most likely corresponding to 
the des-TMS cyanohydrin. 
 
1-(2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-5-yl)-3-methylurea (5):  
Procedure is a slight modification to that found in the literature reported by M. 
Michaelides, et al.  To a saturated solution of HCl(g) in anhydrous EtOH (45 ml) cooled 
by an ice/water bath was added crude 4 (~4.70 mmol) as a solution in anhydrous EtOH 
(~5 ml).  HCl(g) was slowly bubbled into the reaction to keep the solution saturated.  The 
rate of addition of HCl(g) was slow enough to maintain the internal reaction temperature 
below 10°C.  After stirring for 2 h, the volatiles were removed in vacuo.  The residue 
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obtained was subjected to a high vacuum (~0.05 torr) for 1 h at rt to remove trace 
volatiles.  The residue 5 was used in the next step without further purification. 
To an ice/water cooled solution of 5 (~4.70 mmol) dissolved in anhydrous 
dichloromethane (20 ml) and trimethylamine (2.62 ml, 18.8 mmol, 4 equiv.) was added 
triphosgene (697 mg, 2.35 mmol) in small portions over 10 min.  After addition was 
complete, the ice/water bath was removed and the reaction was allowed to stir at rt for 3h.  
The pH of the reaction was adjusted with 6N aq. HCl to 5 and stirred for an additional 1 
h.  The volatiles were removed and the reaction purified on a C18 flash column using a 0 
to 100% gradient of water (containing 0.05% Tfa by volume) and acetonitrile (0.05% 
Tfa).  The fractions containing the product were further purified on a silica gel flash 
column using a gradient of 0 to 10% MeOH/CHCl3 to obtain 45 mg of 6 as an off-white 
solid (3% yield).  1H NMR (500 MHz, DMSO-d6) ∂ 8.65 (s, 1H), 7.75 (s, 1H), 7.48 (t, J 
= 2.04 Hz, 1H), 7.22 - 7.41 (m, 2H), 6.03 (d, J = 4.72 Hz, 1H), 3.58 - 3.79 (m, 2H), 2.64 
(d, J = 4.56 Hz, 3H). LC-MS: Rt=1.46 min; m/z=276.1 [M+H]+ 
 
N-(4-fluorobenzyl)-2-(5-(3-methylureido)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-
oxazolidin]-3'-yl)-N-((S)-1,1,1-trifluoropropan-2-yl)acetamide (228-1):  To a solution of 
6 (23 mg, 0.08 mmol, 1 equiv.) in anhydrous DMF (139 uL) was added 2 (28.5 mg, 0.08 
mmol, 1 equiv.) and K2CO3 (34.6 mg, 0.24 mmol, 3 equiv.).  After stirring for 6 h at rt, 
the reaction was diluted with water and EtOAc.  After extraction with EtOAc (3 x 15 ml), 
the combined organic layers were washed with brine and dried with anhydrous MgSO4.  
The volatiles were removed and the reaction purified on a C18 flash column using a 0 to 
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100% gradient of water and acetonitrile.  The fractions containing the product were 
further purified on a silica gel flash column using a gradient of 0 to 10% Hexanes/EtOAc  
to obtain 21 mg of 228-1 (mixture of diastereomers) as an off-white solid (47% yield).  
1H NMR (500 MHz, METHANOL-d4) ∂ 7.51 (br. s., 1H), 7.31 - 7.46 (m, 2H), 7.09 - 
7.31 (m, 3H), 7.02 (q, J = 8.02 Hz, 1H), 5.46 (br. s., 1H), 5.00 (dd, J = 8.17, 16.19 Hz, 
1H), 4.71 - 4.82 (m, 1H), 4.52 - 4.63 (m, 2H), 4.32 (dd, J = 13.36, 16.66 Hz, 1H), 3.13 - 
3.26 (m, 1H), 2.99 - 3.13 (m, 1H), 2.66 - 2.85 (m, 4H), 2.45 - 2.62 (m, 1H), 1.44 (d, J = 
6.60 Hz, 1H), 1.36 (d, J = 7.23 Hz, 2H). LC-MS: Rt=2.61 min; m/z=537.0 [M+H]+ 
 
“Spirocyclic compound as HAT inhibitors and their preparation”  Michaelides, Michael; Hansen, Todd; Dai, Yujia; 
Zhu, Guidong; Frey, Robin; Gong, Jane; Penning, Thomas; Curtin, Michael; McClellan, William; Clark, Richard; et al 
From PCT Int. Appl. (2016), WO 2016044770 A1 20160324 
 
 “Mild and Efficient Silylcyanation of Ketones Catalyzed by N-Methylmorpholine N-Oxide” Kim, S.S.; Kim, D.W.; 
Rajagopal, G. Synthesis 2004, 213-216. 
 
 
 
 
*Synthesis steps and figure produced by David Meyers 
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Appendix 4 – Characterization of compound R 	
Previously, inhibitors of p300 HAT function were largely derived from natural 
compounds, which lack specificity (Dekker and Haisma, 2009). In order to increase 
efficacy and selectivity, bi-substrate analogs such as Lys-CoA was synthesized and 
characterized. However, those analogs were also met with challenges due to its poor 
bioavailability. Recently, a virtual ligand screen identified a selective and potent inhibitor 
of p300 HAT activity known as C646 based on the identified structure of the p300 HAT 
domain (Bowers et al., 2010) . Our group has applied C646 in human melanoma and 
identified that C646 is a potent inhibitor of melanoma proliferation by promoting cellular 
senescence (Yan et al., 2013). Interestingly, C646 treatment in human melanoma cells did 
not inhibit MITF expression, which is contradictory to what we have identified using 
shRNA and CRISPR p300 silencing techniques (Figure II-5 & Appendix figure 1.D). It is 
possible that C646 is less than a potent inhibitor of p300/CBP HAT activity and that it 
may result in reduced, yet adequate, acetylation and subsequent activation of MITF 
promotor region (Figure II-9). 
In order to utilize a more potent form of p300/CBP HAT inhibitor, our group 
initially synthesized and characterized a compound named R (Appendix 2 and 3). 
Compound R is a proprietary compound synthesized and developed by Dr. Philip A. Cole 
(Department of Pharmacology & Molecular Sciences, Johns Hopkins School of 
Medicine), which is an immediate predecessor to 228-1. It is estimated that compound R 
is at least 20-fold more potent than C646 based on comparable assay conditions (Dancy 
et al., 2012).  
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First, we decided to compare compound R to its predecessor, C646. Since C646 
inhibits cell proliferation, we aimed to see if MAPK and AKT pathways are affected 
following compound R treatment. We identified that the expression of Cyclin A is 
reduced following C646 and compound R treatment (10µM each). Interestingly, 
phosphorylation of AKT, which is a potent pro-proliferation signal associated with 
mTOR pathway, is paradoxically increased with C646 treatment while it was inhibited 
with R treatment (Appendix figure 4 and 5). Although both compounds inhibit the 
expression of a pro-cell cycle protein Cyclin A, they might be involved in different 
signaling pathways. Furthermore, we demonstrate that phosphorylation of ERK is not 
affected following the treatment with C646 or compound R, indicating that both 
compounds function in MAPK- independent ways. Strikingly, compound R treatment 
completely ablated the expression of MITF while C646 did not affect the expression of 
MITF (Appendix figure 6). This result indicates that compound R inhibits p300/CBP 
HAT activity more specifically and adequately than that of C646 at the promoter region 
of MITF. There may exist threshold of acetylation at the promoter region of MITF that 
allows the initiation of MITF transcription. C646 may not provide potent inhibition of 
p300-mediated HAT activity, therefore, unable to block MITF transcription. It is also 
possible that compound R more effectively shuts down the transcription of upstream 
regulators of MITF such as SOX10, PAX3, LEF1 and CREB.  
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Appendix figure 4. C646 induces phosphorylation of AKT and concomitantly reduces Cyclin A expression. 
Four human melanoma cell lines were treated with vehicle control (DMSO) and C646 (10 µM) for 48 hours. Cells were 
subsequently lysed and harvested for protein samples and further subjected to western blot analysis. We detected 
increase in AKT phosphorylation in three out of four melanoma cell lines. We identified that all four cells lines tested 
showed reduced expression of Cyclin A. Furthermore, C646 does not affect ERK pathway or overall PTEN protein 
expression in human melanoma cells.  
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Appendix figure 5. Compound R inhibits phosphorylation of AKT and Cyclin A expression. 
Four human melanoma cell lines were treated with vehicle control (DMSO) and compound R (10 µM) for 48 hours. 
Cells were subsequently lysed and harvested for protein samples and further subjected to western blot analysis. We 
detected reduction in AKT phosphorylation and Cyclin A expression in all four melanoma cell lines tested. Compound 
R does not affect phosphorylation of S6, which is downstream of AKT/mTOR pathway. -: DMSO, A and B: inactive 
homologues of Compound R. 
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Appendix figure 6. Compound R is a potent inhibitor of MITF expression. 
Two human melanoma cell lines, which express high and low levels of MITF were treated with vehicle control 
(DMSO), compound R (10 µM), and C646 (10 µM) for 48 hours. Cells were subsequently harvested for protein 
samples and further subjected to western blot analysis. We detected a notable reduction in MITF expression following 
treatment with compound R, but not C646 in melanoma cells with high endogenous expression of MITF (WM983B). 
Based on two melanoma cell lines, it seems that phosphorylation of CREB, a potent transcription factor for MITF, was 
paradoxically enhanced following R treatment. D: DMSO, R: compound R.  
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Appendix 5 –  Acetylation prolongs the half-life of MITF protein 
 Protein homeostasis, proteostasis, is a crucial process that occurs as a part of 
normal cell maintenance. Accumulation of damaged proteins may impose great harm to 
normal cell physiologic processes and accelerate cell damage and aging. Underlying 
systems that contribute to cellular protein quality controls such as chaperones proteins, 
autophagy process, and ubiquitinin-proteosome system would ensure the integrity of 
cells.  
In melanocytes and melanoma, it is reasonable to propose that important lineage-
specific transcription factors such as MITF is tightly controlled by mechanisms that 
govern proteostasis. It is well known in the literature that mutated MAPK pathway, 
BRAF, is implicated in inducing MITF phosphorylation, which potentiates the 
transcription activity. At the same time, the phosphorylation promotes uniquitination, 
which accelerates the degradation of MITF. Recently, Zhao and colleagues reported an 
interesting finding regarding deubiquitinating enzyme, named ubiquitin-specific protease 
13 (USP13), which appears to be involved in MITF deubiquitination (Zhao et al., 2011). 
Through this process, USP13 stabilizes and upregulates MITF protein levels. This finding 
suggests an interesting druggable target for melanoma therapy since MITF level is 
associated with poor clinical outcome in melanoma patients. 
 In a different light, we were interested whether acetylation could potentially 
protect MITF from degradation through ubiquitinization. It is well-established that 
acetylation of proteins plays a major role in determining protein integrity and half-life by 
protecting proteins from ubiquitinin-proteosome system. Since MITF protein possesses 
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two acetylation sites in physical proximity to ubiquitinin sites, we hypothesized that 
inhibition of p300/CBP HAT-mediated acetylation of MITF protein would accelerated 
degradation. We treated WM983B cells with compound R, which is a potent p300/CBP 
HAT inhibitor, and harvested protein at 0.5, 1, 2, 4, and 8 hours post-treatment in vitro. 
In addition, we also treated and harvested cells that are treated with compound R and 
MG-132, which is a proteasome inhibitor. We found that the half-life of MITF protein is 
about 2 hours following compound R treatment. When cells were treated together with 
MG-132 and compound R, we observed doubling of MITF half-life to about 4 hours. 
This result may imply that acetylation of MITF protein provides some level of protection 
against proteasome-mediated degradation. However, we were unable to quantify the 
direct relationship between acetylation level and ubiquitination level following 
compound R treatment at the specific sites on MITF protein. Further experiments such as 
site-directed mutagenesis of the acetylation and ubiquitination site may provide further 
insights.  
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Appendix figure 7. Rapid degradation of MITF protein following compound R treatment is delayed with 
proteasome inhibitor MG-132. 
Compound R time-course treatment (0.5 – 8 hrs) was initiated on WM983B cell line in vitro with or without concurrent 
proteasome inhibitor MG-132 treatment. With compound R alone, half-life of MITF protein is about 2 hours. When 
treated together with MG-132, MITF half-life is prolonged to about 4 hours. Illustration on the top demonstrates the 
p300/CBP binding sites, ubiquitinin and acetylation sites on MITF protein. 
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Appendix 6 – ChIP-PCR primer sequences for the characterization of MITF gene 
upstream regulatory region. 
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